2026 NPPES data Gynecologic Oncology Physician NPI 1447201827
Verify on CMS →

JOHN VILLENEUVE

Gynecologic Oncology Physician in WEST READING, Pennsylvania. CMS National Plan and Provider Enumeration System profile including specialty classification, practice address, and Medicare prescribing data when reported.

Federal data — no proprietary rating. PlainDoctor publishes the actual CMS NPPES and Medicare records — NPI registration, specialty, practice location, and prescribing data — without a composite score or editorial opinion on top. Every field traces to a federal source.
Prescribing volume
314
Medicare Part D claims · 82 beneficiaries · Gynecologic Oncology Physician avg: 188
Generic prescribing
78%
generic claims · 22% brand-name · higher generic rates reduce patient out-of-pocket costs
MIPS score
86.1318/100
▲ 3 pts above national avg 83.1 · [object Object]
Industry payments
$121.68
5 payments · CMS Open Payments (Sunshine Act)

What the federal data shows

JOHN VILLENEUVE reported a CMS MIPS final score of 86.1318/100 — above the 83.1 national average — and filed 314 Medicare Part D claims in 2023.

86.1318/100
MIPS score · +3 vs avg
314
Part D claims, 2023
78%
generic prescribing
Likely
board-certified (heuristic)

Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) — no proprietary rating or editorial opinion is applied.

JOHN VILLENEUVE's MIPS score vs every scored U.S. clinician

CMS Merit-based Incentive Payment System (MIPS) final score, 2023 — the federal quality measure

86 Top 48% higher than 52% of 477,587 scored providers

0–10: 8,684 scored providers (2%). Below this entry. 10–20: 3,008 scored providers (1%). Below this entry. 20–30: 3,069 scored providers (1%). Below this entry. 30–40: 2,746 scored providers (1%). Below this entry. 40–50: 2,928 scored providers (1%). Below this entry. 50–60: 5,882 scored providers (1%). Below this entry. 60–70: 13,906 scored providers (3%). Below this entry. 70–80: 118,074 scored providers (25%). Below this entry. 80–90: 129,887 scored providers (27%). This entry sits in this band. 90–100: 189,403 scored providers (40%). Above this entry. This provider 0 100 every MIPS-scored clinician, bucketed by value

Each bar is a band; taller bars hold more scored providers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source CMS Merit-based Incentive Payment System (MIPS) · 2023

Board certification likely (heuristic — not verified)

JOHN VILLENEUVE practices in an ABMS-board-eligible specialty and shows active CMS Medicare participation + MIPS quality reporting + 2 hospital affiliations — signals consistent with board-certified status. For verified board certification, see CertificationMatters.org (the official ABMS public lookup).

What does the federal data show about JOHN VILLENEUVE?

High performer (top quartile)

NPI registry status

Active

Issued 05/12/2006

NPI 1447201827

Primary specialty

Gynecologic Oncology Physician

Niche

1,360 US NPIs in this specialty

Medicare Part D claims

314 67% vs specialty avg

2023 prescription claims

Specialty avg: 188

MIPS final score

86.1318/100 3.031800000000004% pts

Above neutral band

vs 83.1 national avg

Specialty distribution in Pennsylvania

How Gynecologic Oncology Physician compares to other specialties among Pennsylvania providers

Pennsylvania providers

Gynecologic Oncology Physician share within Pennsylvania

1. Gynecologic Oncology Physician42%2. Internal medicine21%3. Family medicine17%4. Surgical12%5. Pediatric8%
Gynecologic Oncology Physician share within Pennsylvania

Medicare quality performance — MIPS

JOHN VILLENEUVE's 2023 MIPS final score plotted against the Gynecologic Oncology Physician national average

High performer (top quartile)
MIPS Final Score
86.1318/100
vs 83.1 national avg · 2023 performance year

MIPS final score (Gynecologic Oncology Physician) — 86.1318/100 vs national avg 83.1

0%100%National avg83%86.1%
MIPS final score (Gynecologic Oncology Physician) — 86.1318/100 vs national avg 83.1

The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.

Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).

JOHN VILLENEUVE appears in the CMS NPPES registry as a Gynecologic Oncology Physician provider at 6TH AVENUE AND SPRUCE STREET, WEST READING, PA, 19611, with a listed phone of (610) 988-8905. NPI 1447201827 was issued on 05/12/2006. Because NPPES data is self-reported by the provider and refreshed monthly, the address, phone, and specialty reflect what VILLENEUVE most recently submitted to CMS rather than a vetted directory listing, which is why patients should always confirm the practice is still at this location before scheduling.

Medicare Part D records for calendar year 2023 show 314 prescription claims written by this provider, covering 82 Medicare beneficiaries and totaling roughly $708K in drug spend, split 22% brand-name and 78% generic by claim count, with an opioid prescribing rate of 16.2%. These figures capture only Medicare Part D — commercial insurance, Medicaid, and cash-pay prescriptions are not included, and any drug-beneficiary cell under 11 is suppressed by CMS for patient privacy. On the CMS Merit-based Incentive Payment System, this provider earned a Final Score of 86.1318/100 for the 2023 performance year (Quality 81.9126, Cost 62.8334), compared with the national average of 83.1.

Gynecologic Oncology Physician is a narrow specialty nationwide, with 1,360 enrolled providers across 49 states and an average of 188 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline. Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist — always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.

Practice Address

6TH AVENUE AND SPRUCE STREET
WEST READING, PA 19611

Provider Details

NPI 1447201827
Specialty Gynecologic Oncology Physician
Gender Male
NPI Issued 05/12/2006

CMS Quality Score (MIPS)

Merit-based Incentive Payment System (MIPS) scores from CMS, 2023 performance year.

86.1318
Final Score
Avg: 83.1
81.9126
Quality
62.8334
Cost
99
Promoting Interoperability

Reporting: Group practice

Hospital and facility affiliations

Facilities where JOHN VILLENEUVE bills Medicare from. Star ratings (1-5) are CMS Hospital Compare's "Hospital overall rating" — a composite of mortality, readmission, patient experience, safety, timely care, and efficient use of medical imaging measures. Source: CMS Care Compare.

READING HOSPITAL
★★★★☆ 4/5
WEST READING, PA
Acute Care Hospitals
CMS CCN: 390044
KEYSTONE REHABILITATION SYSTEMS INC
BIRDSBORO, PA

Affiliations sourced from CMS Doctors and Clinicians National Downloadable File; hospital ratings from CMS Hospital General Information dataset (cross-referenced by facility name + state).

Industry payments received (2024) — CMS Open Payments transparency data

The federal Physician Payments Sunshine Act (part of the Affordable Care Act) requires drug and medical-device manufacturers + group purchasing organizations to publicly report payments and other transfers of value to physicians and teaching hospitals. The data below covers 2024 for JOHN VILLENEUVE. Source: openpaymentsdata.cms.gov.

Total received

$122

Largest payer

Incyte Corporation

Most common payment type

Food and Beverage

Industry payments are not necessarily indicators of bias — they include research funding, consulting fees for evidence-based work, royalties for inventions, food at conferences, and similar items. The disclosure exists for transparency. Read our methodology for how we interpret this data.

License & disciplinary context — Pennsylvania PA-BOM 2023 annual report

Aggregate state board data only — NOT a determination of any individual provider's status. The figures below describe statewide disciplinary activity across all ~45K Pennsylvania medical licensees in 2023 — they are NOT specific to JOHN VILLENEUVE. To verify JOHN VILLENEUVE's current license status, search the PA-BOM public license lookup directly, or check the Federation of State Medical Boards (FSMB) verification service.

133
Total board actions, Pennsylvania 2023
Across 129 cases
2.96
Actions per 1,000 licensees
Pennsylvania statewide rate
probation
Most common action type
48 cases

PA-BOM publishes annual disciplinary statistics as part of public-record reporting under each state's Administrative Procedure Act. See the full breakdown by action type and year on the Pennsylvania disciplinary trends page. Cross-checked against FSMB U.S. Medical Regulatory Trends.

Brand vs generic prescribing mix · Typical

JOHN VILLENEUVE — brand share 22.0%
Specialty average (est.)

22% brand-name claims vs 78% generic, on 314 2023 Medicare Part D claims.

The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.

Medicare Part D Prescribing Data

CMS Medicare Part D prescriber-level data for calendar year 2023.

314
Total Claims
$708K
Total Drug Cost
82
Medicare Beneficiaries

Prescribing Breakdown

30-Day Fills
356
Total Day Supply
6,584
Brand vs Generic
22% brand / 78% generic
Brand Drug Cost
$703K
Generic Drug Cost
$5K
Opioid Claims
51 (16.2% rate)

Patient Demographics

Average Patient Age
71.2 years
Avg HCC Risk Score
1.49
Gender Split
100% female / 0% male

Top Prescribed Drugs (Medicare Part D)

Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.

What JOHN VILLENEUVE prescribes most

Top Medicare Part D drugs by claim count, 2023

claims
Source CMS Medicare Part D Prescriber Public Use File As of 2023
Drug Claims
Zejula
Niraparib Tosylate
46
Prochlorperazine Maleate
44
Oxycodone-Acetaminophen
Oxycodone Hcl/Acetaminophen
40
Ondansetron Hcl
32
Clobetasol Propionate
22
Dexamethasone
20
Enoxaparin Sodium
19
Lidocaine-Prilocaine
Lidocaine/Prilocaine
19
Anastrozole
15
Clotrimazole-Betamethasone
Clotrimazole/Betamethasone Dip
14

* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.

Gynecologic Oncology Physician Overview

How JOHN VILLENEUVE fits within the Gynecologic Oncology Physician landscape nationally.

1,360
Gynecologic Oncology Physician Providers in US
49
States with Gynecologic Oncology Physician
188
Avg Claims per Provider

JOHN VILLENEUVE's 314 claims are above the specialty average of 188.

Nearby Gynecologic Oncology Physician Providers in Pennsylvania

Other clinicians with the same primary specialty enrolled in Pennsylvania, drawn from the same CMS NPPES roster as VILLENEUVE.

Compare Gynecologic Oncology Physician nationally: see state-by-state distribution →

Frequently Asked Questions

What is JOHN VILLENEUVE's specialty?
JOHN VILLENEUVE specializes in Gynecologic Oncology Physician and practices in WEST READING, Pennsylvania.
How much does JOHN VILLENEUVE prescribe under Medicare Part D?
In 2023, JOHN VILLENEUVE wrote 314 Medicare Part D claims totaling $708K in drug costs for 82 beneficiaries.
What is JOHN VILLENEUVE's Medicare quality score?
JOHN VILLENEUVE has a CMS MIPS Final Score of 86.1318/100 (Quality: 81.9126, Cost: 62.8334). The national average MIPS Final Score is 83.1. Source: CMS Merit-based Incentive Payment System (MIPS) 2023.
Where is JOHN VILLENEUVE located?
JOHN VILLENEUVE is located at 6TH AVENUE AND SPRUCE STREET, WEST READING, PA, 19611. Phone: (610) 988-8905.
What is JOHN VILLENEUVE's NPI number?
JOHN VILLENEUVE's National Provider Identifier (NPI) is 1447201827, issued on 05/12/2006.
Does JOHN VILLENEUVE prescribe more brand-name or generic drugs?
JOHN VILLENEUVE's prescribing is 22% brand-name and 78% generic drugs by claim count, with $703K in brand drug costs.
Does JOHN VILLENEUVE prescribe opioids?
Yes, JOHN VILLENEUVE had 51 opioid claims in 2023 with an opioid prescribing rate of 16.2%.
How many Gynecologic Oncology Physician providers are there in the US?
There are 1,360 Gynecologic Oncology Physician providers across 49 states in the US. The average Gynecologic Oncology Physician provider writes 188 Medicare Part D claims per year.
What drugs does JOHN VILLENEUVE prescribe most often?
Based on 2023 Medicare Part D data, JOHN VILLENEUVE's most frequently prescribed drugs include Zejula, Prochlorperazine Maleate, Oxycodone-Acetaminophen. This reflects Medicare Part D prescriptions only and does not include commercial insurance or other payer types.
Does JOHN VILLENEUVE accept Medicare?
JOHN VILLENEUVE appears in CMS Medicare data with 314 Part D claims and 82 Medicare beneficiaries in 2023. Contact the provider's office directly to confirm current Medicare enrollment and accepted plans.
How can I verify JOHN VILLENEUVE's credentials?
JOHN VILLENEUVE's NPI is 1447201827. You can verify this through the NPPES NPI Registry, check state medical board records, and confirm board certification through the ABMS or AOA.

Data Sources

Provider Directory
CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
Specialty Classification
NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
Prescribing Data
CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
Quality Performance
CMS Merit-based Incentive Payment System (MIPS) — 2023 performance year.
Limitations
Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.

See our complete data methodology for details on how we collect and process government data.

Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).

Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology